Implementation Research on Telehealth Strategies to Support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients

0
1

Opportunity ID:334702
Opportunity Number:RFA-PS-22-002
Opportunity Title:Implementation Research on Telehealth Strategies to Support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.941
Eligible Applicants:State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:The following types of Higher Education Institutions are always encouraged to apply for CDC support as Non-profit Public or Private Institutions of Higher Education: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Nonprofits (Other than Institutions of Higher Education) Eligible Agencies of the Federal Government U.S. Territory or Possession Faith-based or Community-based Organizations Regional Organizations Bona Fide Agents: a Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with "Other Attachment Forms" when submitting via https://www.grants.gov Federally Funded Research and Development Centers (FFRDCs): FFRDCs are operated, managed, and/or administered by a university or consortium of universities, other not-for-profit or nonprofit organization, or an industrial firm, as an autonomous organization or as an identifiable separate operating unit of a parent organization. A FFRDC meets some special long-term research or development need which cannot be met as effectively by an agency's existing in-house or contractor resources. FFRDC's enable agencies to use private sector resources to accomplish tasks that are integral to the mission and operation of the sponsoring agency. For more information on FFRDCs, go to https://ecfr.io or https://www.nsf.gov/statistics/ffrdclist/
Agency Code:HHS-CDC-HHSCDCERA
Agency Name:Department of Health and Human Services
Centers for Disease Control and Prevention – ERA
Posted Date:Jul 13, 2021
Last Updated Date:Jul 13, 2021
Estimated Synopsis Post Date:Dec 01, 2021
Fiscal Year:2022
Award Ceiling:$450,000
Award Floor:$400,000
Estimated Total Program Funding:$3,600,000
Expected Number of Awards:2
Description:The purpose of this notice of funding opportunity (NOFO) is to solicit research applications to evaluate the effectiveness of telemedicine to improve adherence to HIV prevention and treatment medication while also exploring the “implementability” of its practice into routine care. Specifically, this NOFO will, via a hybrid effectiveness-implementation research design: 1) evaluate the effectiveness of telemedicine and supportive strategies to allow for retention in care and maintenance of antiretroviral therapy (ART) medication adherence among clinically stable people with HIV (PWH) and pre-exposure prophylaxis (PrEP) medication adherence among those at risk for HIV infection, especially among racial/ethnic minorities, men who have sex with men (MSM), and transgender women and 2) identify potential implementation challenges by evaluating the delivery of these strategies. Projects should evaluate the cost-effectiveness of providing differentiated service delivery (DSD) options that include telemedicine to patients on ART or on PrEP. DSD is a recommended approach to service delivery that simplifies and/or adapts HIV prevention and treatment services to more effectively and efficiently serve the needs of people living with, and at risk of acquiring, HIV while reducing unnecessary burdens on the healthcare system. The goals of the research are: 1) to evaluate three recommended strategies for DSD for clinically stable patients (a. telehealth appointments for PrEP and ART with multi-month prescription refills; b. biospecimen sample self-collection for routine screenings; and c. supplemental support delivered by specialized staff such as community health workers or patient navigators); 2) to determine which strategy or combination of strategies is associated with retention in care, medication adherence, viral suppression and prevention of HIV infection, and costs to implement each approach; 3) to evaluate the cost effectiveness of implementing these strategies in comparison to the standard, in-person clinical visit model of care; and 4) to identify potential challenges to implementation and determine the acceptability, feasibility and sustainability of implementing these strategies into routine practice. Ultimately, this NOFO aims to support research to identify, via cost analysis, process and outcome evaluation and patient and provider feedback, which elements of implementation provide the most impact for the least cost to patients, providers, and clinics.
Version:1





Visit the Official Webpage For More Details on Implementation Research on Telehealth Strategies to Support Retention in Care and Treatment among Antiretroviral Therapy (ART) Patients and Pre-exposure Prophylaxis (PrEP) Clients

LEAVE A REPLY

Please enter your comment!
Please enter your name here